DKK1 and osteoporosis: Romosozumab, an inhibitor of sclerostin, is already used as an anabolic treatment in osteoporosis with an acceptable tolerability profile.100 Studies on molecules targeting Dkk-1 in various malignancies are in early stages.101,102